Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Jun 18
Show Filter
7:00am - 8:00am

Registration

More
8:00am - 8:15am

Conference Opening and Welcome

  • Anthony Davies - Founder & CEO, Dark Horse Consulting, USA
More
Showing of Streams
9:45am - 10:30am

Morning Coffee and Networking

More
Showing of Streams
Showing of Streams
3:15pm - 4:00pm

Afternoon Coffee

More
Showing of Streams
5:00pm - 6:00pm

Cocktail Reception in Exhibit & Poster Hall

More
7:00am - 8:00am 60 mins
Registration
8:00am - 8:15am 15 mins
Conference Opening and Welcome
  • Anthony Davies - Founder & CEO, Dark Horse Consulting, USA
8:15am - 8:45am 30 mins
Solid Tumours – New Modalities, Combination Therapies and Novel Cancer Treatment
Allo CAR T TM targeting CD70 for the treatment of renal cell carcinoma
  • Siler Panowski - Associate Director, Solid Tumors, Allogene Therapeutics, USA
8:45am - 9:15am 30 mins
Info
Solid Tumours – New Modalities, Combination Therapies and Novel Cancer Treatment
Safety and efficacy of TCR-mimic technology in hematologic and solid cancers, from discover concept to in-vitro and in-vivo validation to clinical results
  • Bijan Nejadnik - Chief Medical Officer, Eureka Therapeutics

The advents of the genetically modified T cells, specially the CAR-T and TCR-T cell technologies represents one of the most astounding steps in cancer therapy. However, those technologies have had major challenges:

CRS and Neurotoxicity are the major safety issues, Especially in hematologic malignancies

  • In solid tumors the antigen accessibility and thus lack of efficacy, as well as cross reactivity have been major impediments
  • A new TCR-mimic technology intends to address both limitations
  • The models (preclinical and human) used in are CD 19 positive NHL and AFP+HCC
9:15am - 9:45am 30 mins
Solid Tumours – New Modalities, Combination Therapies and Novel Cancer Treatment
Repurposing Endogenous Immune Pathways to Tailor and Control Chimeric Antigen Receptor T-cell Functionality
  • Julien Valton - Team Leader Innovation, Cellectis, USA
9:45am - 10:30am 45 mins
Morning Coffee and Networking
10:30am - 11:00am 30 mins
Info
Solid Tumours – New Modalities, Combination Therapies and Novel Cancer Treatment
CAR Macrophage Immunotherapy to target Solid Tumors
  • Michael Klichinsky - Co-Founder, Carisma Therapeutics
  • Does this offer an opportunity to attack solid tumors?
  • Macrophages and their ability to penetrate tumor nodules
  • Will they allow for a more robust immune response?
11:00am - 11:30am 30 mins
Info
Solid Tumours – New Modalities, Combination Therapies and Novel Cancer Treatment
3T Bioscience Case Study
  • Hanspeter Gerber - SVP & CSO, 3T Biosciences

While sequencing of TCRs (T-cell receptors) from tumor infiltrating lymphocytes (TILs) yields valuable information regarding T-cell clonality, the nature of the antigens recognized TCRs remains largely elusive. To overcome these current limitations in target antigen identification of TCRs, 3 T Biosciences has developed a high throughput, yeast display technology platform to identify cognate ligands recognized by the most prominent TCRs expressed on TILs. The 3T platform is based on a series of highly-diverse, unbiased peptide-HLA (human leukocyte antigen) yeast-display libraries representing the major allotypes (HLA class I+II) fused to a comprehensive set of peptides covering all exome sequences (Birnbaum et al., Cell 2014). This method has been applied successfully to identify novel ligands for TCRs of unknown specificities, including novel, shared antigens present across cancer patients and tumor indications (Gee et al., Cell 2018).

For the development of adoptive T-cell therapies, TCRs inducing the highest level of T-cell activation and anti-tumor activities were frequently selected for clinical development. In contrast, the preclinical safety assessment of TCRs has been hampered due to the lack of appropriate TCR screening technology and preclinical animal models to select against TCRs binding to additional pMHC complexes present on normal tissues. To overcome these limitations, we took advantage of our yeast display technology to monitor differences in target antigen specificity between lead TCRs and selected the most active and tumor specific TCRs for further development. An update on the preclinical development of our lead TCR-T and cancer vaccines programs will be provided.

11:30am - 12:00pm 30 mins
Info
Solid Tumours – New Modalities, Combination Therapies and Novel Cancer Treatment
Developing an Allogeneic TCR-T Approach based on Gamma Delta T Cells
  • Ali Mohamed - VP, CMC, Immatics, USA

Case study

12:00pm - 12:30pm 30 mins
Info
Solid Tumours – New Modalities, Combination Therapies and Novel Cancer Treatment
dCas9/CAR T platform: Efficacy and safety all-in-one therapy
  • Monique Dao - Senior Director of I/O Preclinical Dev, Refuge Biotechnologies, USA

Combination of CAR T cell therapy with immune checkpoint (ICP) inhibitors is a transformative therapy that may produce sustained clinical benefits for cancer patients. However, as ICPs function as "immune-brakes", systemic administration of ICP inhibitors can elicit immune-related adverse events such as colitis, pneumonitis, and hepatitis. To reduce ir-SAEs without comprising anti-tumor efficacy, Refuge Biotechnologies has developed a proprietary CAR-T platform with an integrated dCas9 transcriptional modular which downregulate inhibitory receptor(s) in CAR-T cells upon tumor recognition. The goal is to deliver an effective and safer therapy to cancer patients.

1:45pm - 2:15pm 30 mins
Safety Switches, Synthetic Biology and Mechanisms to Improve Safety and Efficacy
Improving the in vivo persistence and function of tumor-specific T-cells
  • Cliona Rooney - Professor, Baylor College of Medicine
2:15pm - 2:45pm 30 mins
Safety Switches, Synthetic Biology and Mechanisms to Improve Safety and Efficacy
Small molecule CAR T cell control: making the Switch
  • Stephen Santoro - Principal Scientist, Kite Pharma, a Gilead Company, USA
2:45pm - 3:15pm 30 mins
Safety Switches, Synthetic Biology and Mechanisms to Improve Safety and Efficacy
Genetic modification of T cells to express CD19-specific CAR in two days
  • Harjeet Singh - Instructor, Department of Pediatrics, UT MD Anderson Cancer Center, USA
3:15pm - 4:00pm 45 mins
Afternoon Coffee
4:00pm - 4:30pm 30 mins
Safety Switches, Synthetic Biology and Mechanisms to Improve Safety and Efficacy
Triumvira Immunologics Case Study
  • Jonathan Bramson - Co-Founder & CSO, Triumvira Immunologics, Inc.
4:30pm - 5:00pm 30 mins
Info
Safety Switches, Synthetic Biology and Mechanisms to Improve Safety and Efficacy
961 GM-CSF Blockade during Chimeric Antigen Receptor T Cell Therapy Reduces Cytokine Release Syndrome and Neurotoxicity and May Enhance Their Effector Functions
  • Cameron Durrant - Chairman and CEO, Humanigen, Inc.

Despite its efficacy, chimeric antigen receptor T-cell therapy (CART) is limited by the development of cytokine release syndrome (CRS) and neurotoxicity (NT). While CRS is related to extreme elevation of cytokines and massive T cell expansion, the exact mechanisms for NT have not yet been elucidated. Preliminary studies suggest that NT might be mediated by myeloid cells that cross the blood brain barrier. This is supported by correlative analysis from CART19 pivotal trials where CD14+ cell numbers were increased in the cerebrospinal fluid of patients that developed severe NT (Locke et al, ASH 2017). Therefore, we aimed to investigate the role of GM-CSF neutralization in preventing CRS and NT after CART cell therapy via monocyte control.

5:00pm - 6:00pm 60 mins
Cocktail Reception in Exhibit & Poster Hall